The study demonstrated that ORR was 30% (8/27) in tissue-positive patients and 27% (7/25) in ctDNA-positive patients, which led to the first approval for trastuzumab plus pertuzumab in HER2-positive CRC in Japan in 2022. This evidence concerns the gene ERBB2 and colorectal carcinoma.